Oncology
ViVac Pharma appoints Keren Leshem as CEO
November 26, 2025CEO, Oncology, ViVac Pharma
Early-stage biotechnology company ViVac Pharma has appointed Keren Leshem as its new CEO. Leshem brings almost 30 years of experience …
Rethinking oncology trial endpoints with generalised pairwise comparisons
November 4, 2025Research and Development EMA, FDA, Oncology, One2Treat, clinical trials, generalised pairwise comparisons, net treatment benefit, oncology
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …
Five Facts about Breast Cancer
October 2, 2025Medical Communications Breast Cancer Awareness Month, Five Facts, Oncology, breast cancer
1 There are striking inequities in breast cancer burden regarding the Human Development Index (HDI), the United Nation’s measure of …
Unlocking nature’s pharmacy: how tea leaves and marine organisms could help transform breast cancer treatment
October 2, 2025Research and Development King Abdullah University of Science and Technology, Oncology, natural products chemistry, triple-negative breast cancer
Looking beyond synthetic chemistry to unlock powerful, naturally derived medicines Each year, World Breast Cancer Awareness Month serves as a …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
September 23, 2025Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
Er-Kim to distribute CNX Therapeutics’ oncology drugs across Europe and Turkey
August 29, 2025Logistics & Distribution, Manufacturing and Production, Mergers and Acquisitions CNX Therapeutics, Corporate, Er-Kim, Oncology, central nervous system disorders, critical care
Turkish pharma company, Er-Kim, has signed a distribution agreement with CNX Therapeutics to expand access to a portfolio of oncology …
EMA grants orphan drug designation for Roca’s treatment of radiation maculopathy
August 28, 2025Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy
The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …
Neogap Therapeutics appoints Jonas Mattson to its board of directors
August 26, 2025Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors
Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
August 21, 2025Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …
Graphene-based biosensor to support new lung cancer screening test
August 18, 2025Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …
Anocca secures £32m to advance pancreatic cancer trial
August 18, 2025Research and Development Anocca, Oncology, Pancreatic cancer, research funding
Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development of VIDAR-1, its lead TCR-T …
OS Therapies advances regulatory pathway for bone cancer therapy
August 11, 2025Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma
OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
ARTBIO expands board and establishes technical advisory board
August 11, 2025Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals
ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …
Faron reports increased remission rate in trial for myelodysplastic syndrome candidate
August 7, 2025Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome
Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …
FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate
August 6, 2025Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma
The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
